Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma
Pancreatic Neoplasms, Adenocarcinoma
About this trial
This is an interventional treatment trial for Pancreatic Neoplasms focused on measuring Advanced Stage, Chemotherapy Naive
Eligibility Criteria
Inclusion Criteria: Must have pathological diagnosis recurring or metastatic Pancreatic Adenocarcinoma No prior chemotherapy, immunology treatments or hormonal treatments Measurable disease Must be >18 years old ONLY CONTROL ARM IS OPEN TO ACCRUAL Inclusion Criteria: Pregnant and nursing mothers. Psychiatric disorders that would interfere with consent ability. Patients with known brain or leptomeningeal disease. Patients with history of myocardial infarction with in six previous months. Any concurrent illness that would constitute a hazard to participation in study. Known sensitivity to gemcitabine or etanercept. Prior treatment with etanercept.
Sites / Locations
- Ohio State University Medical Center
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Arm I
Arm II
Patients received entanercept 25 mg subcutaneously twice weekly with gemcitabine.
Patients with pancreatic cancer for which treatment with gemcitabine as a single agent is planned will be asked to participate in this trial as a control group.